Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxegol extension study in OIC
NCT01395524Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2011
- Primary completion
- Sep 2012
- Modality
- Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
A Phase 3 trial of naloxegol in opioid-induced constipation (OIC), sponsored by AstraZeneca. Started Jul 2011; status: completed.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01395524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395524.